Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

NCT07049159 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Shigella

Interventions

BIOLOGICAL: ShigETEC vaccine
OTHER: Placebo
BIOLOGICAL: Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU

Sponsor

Eveliqure Biotechnologies GmbH